The health system’s clinicians specializing in brain tumors will use Neosoma’s technology and provide feedback to the company. Additional parts of the collaboration include data-sharing, clinical research and strategic investment from Hackensack, according to a Feb. 24 Neosoma news release.
Neosoma recently received FDA clearance for its AI-based neuro-health software device, Neosoma HGG.
“Neosoma helps to avoid interruptions in care, unnecessary surgeries, and unnecessary changes in therapy,” Joseph Landolfi, DO, a neuro-oncologist and the chief medical officer at the system’s Edison, N.J.-based JFK University Medical Center, said in the release. “The entire team benefits from centralized information, more efficient communication, and treatment protocols tailored to each specific patient.”
